• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

    10/10/23 8:19:59 AM ET
    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Building Products
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUVI alert in real time by email

    Gainers

    SuperCom Ltd. (NASDAQ:SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.

    Immunic, Inc. (NASDAQ:IMUX) shares gained 13.2% to $1.80 in pre-market trading after the company disclosed positive interim data from Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis.

    Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 21.1% to $0.2785 in pre-market trading, after falling 8% on Monday.

    Mobilicom Limited (NASDAQ:MOB) rose 41.1% to $2.05 in pre-market trading, after gaining more than 11% on Monday.

    SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares climbed 18.2% to $2.01 in pre-market trading, after jumping 18% on Monday. Domaine Des Massifs and SMX recently formed a strategic collaboration to revolutionize traceability.

    ContraFect Corporation (NASDAQ:CFRX) rose 16.8% to $0.5277 in pre-market trading, after surging more than 12% on Monday.

    ParaZero Technologies Ltd. (NASDAQ:PRZO) shares jumped 13.8% to $3.07 in pre-market trading. ParaZero Technologies shares jumped 133% on Monday after the company announced an Australian regulator approved the first commercial drone flights in populated areas and near people using the ParaZero safety systems.

    Sonendo, Inc. (NYSE:SONX) gained 11.2% to $0.4172 in pre-market trading, after gaining 23% on Monday. Sonendo recently revealed a Receipt of notice of non-compliance with the NYSE Trading Share Price Listing Rule.

    Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares surged 11% to $1.11 in pre-market trading. Lexicon Pharmaceuticals said INPEFA received preferred formulary status with Express Scripts for Medicare patients.

    ReTo Eco-Solutions, Inc. (NASDAQ:RETO) shares rose 9% to $0.58 in pre-market trading. ReTo Eco-Solutions recently reported a $15 million registered direct offering and $10 million concurrent private placement.

    Losers

    Borqs Technologies, Inc. (NASDAQ:BRQS) fell 50.8% to $0.52 in pre-market trading after declining more than 13% on Monday. Borqs Technologies recently announced a 1-for-12 reverse stock split.

    Phoenix Motor Inc. (NASDAQ:PEV) fell 14.6% to $1.35 in pre-market trading, after surging 58% on Monday. Phoenix Motor said its EdisonFuture subsidiary launched new Proton Exchange Membrane (PEM) solutions for green hydrogen products and production.

    Atreca, Inc. (NASDAQ:BCEL) shares fell 12.8% to $0.2011 in pre-market trading.

    RVL Pharmaceuticals plc (NASDAQ:RVLP) shares fell 11.4% to $0.1689 in pre-market trading, after jumping over 50% on Monday.

    Molekule Group, Inc. (NASDAQ:MKUL) shares fell 10.2% to $0.1158 in pre-market trading after gaining around 5% on Monday.

    Windtree Therapeutics, Inc. (NASDAQ:WINT) fell 9.9% to $1.09 in pre-market trading.

    Applied UV, Inc. (NASDAQ:AUVI) shares fell 9.8% to $0.3121 in pre-market trading. The company recently announced its new product, the Airocide Pro+ air purification system for food preservation, which will be on display at the Global Produce & Floral Show.

    Vascular Biogenics Ltd. (NASDAQ:VBLT) fell 9.1% to $0.2272 in pre-market trading. Vascular Biogenics, during August, posted a narrower loss for the second quarter.

    Maison Solutions Inc. (NASDAQ:MSS) fell 9.2% to $5.90 in pre-market, after dipping 11% on Monday.

    Future FinTech Group Inc. (NASDAQ:FTFT) shares fell 8.7% to $0.95 in pre-market trading.

    Now Read This: Walgreens Likely To Report Lower Q4 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $AUVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUVI
    $BCEL
    $BRQS
    $CFRX

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Immunic Inc.
    $IMUX
    11/7/2025$3.00Buy
    Roth Capital
    Immunic Inc.
    $IMUX
    9/29/2025$13.00Buy
    Chardan Capital Markets
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Immunic Inc.
    $IMUX
    3/25/2025Outperform
    William Blair
    Lexicon Pharmaceuticals Inc.
    $LXRX
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    Immunic Inc.
    $IMUX
    11/25/2024$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    SEC Filings

    View All

    SEC Form EFFECT filed by SMX (Security Matters) Public Limited Company

    EFFECT - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    3/9/26 12:15:11 AM ET
    $SMX
    Industrial Machinery/Components
    Technology

    SEC Form S-8 filed by SMX (Security Matters) Public Limited Company

    S-8 - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    3/6/26 5:25:24 PM ET
    $SMX
    Industrial Machinery/Components
    Technology

    SEC Form 6-K filed by SMX (Security Matters) Public Limited Company

    6-K - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    3/6/26 5:09:59 PM ET
    $SMX
    Industrial Machinery/Components
    Technology

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobilicom Launches SkyHopper MultiBand: Delivering Cybersecure, Expansive Wideband Coverage for Loitering Drones and Robotics

    MultiBand technology designed to further expand SkyHopper SDR DataLinks product line with wider spectrum, longer range, and robust electronic warfare resilience Unified configuration aimed at enabling deployment across the U.S., Europe, NATO and other regions through software-defined band selection Palo Alto, California, March 05, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced the launch of SkyHopper MultiBand, its newest software-defined radio (SDR) data link designed to deliver continuous, cybersecure wideband operations for loitering muniti

    3/5/26 7:30:00 AM ET
    $MOB
    Aerospace
    Industrials

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ReTo Eco-Solutions, Inc. Announces Acquisition of Majority Interest in Seven Arrows Supply Chain Limited

    BEIJING, March 4, 2026 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (NASDAQ:RETO) ("ReTo" or the  "Company"), a manufacturer and distributor of eco-friendly construction materials and intelligent equipment in China, today announced that it has closed the acquisition of 51% equity interest in Seven Arrows Supply Chain Limited, a British Virgin Islands exempted company ("Seven Arrows"). Through its wholly owned subsidiary, Hainan Seven Arrows Supply Chain Co., Ltd., Seven Arrows is primarily engaged in craft beer supply chain management and distribution in China. The acquisition was completed through a share exchange agreement, dated February 27, 2026, by and among the Company, Seven Arrows, and t

    3/4/26 9:00:00 AM ET
    $RETO
    Industrial Machinery/Components
    Industrials

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Human Resources Mcdermott Wendy converted options into 224,406 shares and covered exercise/tax liability with 68,107 shares, increasing direct ownership by 128% to 277,945 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:59 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Partnerships & Corp Strat Martens Rachel Yap converted options into 67,090 shares and covered exercise/tax liability with 35,826 shares (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:20 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Medical Officer Granowitz Craig B converted options into 312,276 shares and covered exercise/tax liability with 109,098 shares, increasing direct ownership by 169% to 323,430 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:19:33 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Immunic with a new price target

    Roth Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $3.00

    11/7/25 8:30:20 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Immunic with a new price target

    Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00

    9/29/25 9:57:47 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/23/26 7:49:43 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

    THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w

    2/26/26 8:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI and Electronic Warfare Are Rewriting the Rules of Modern Defense

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The Department of Defense's total IT budget for fiscal 2026 reached $66 billion, a $1.8 billion increase from 2025, with the Army boosting AI spending by 38.3% and the Air Force increasing force application funding by 143.8%[1]. Congress backed the shift with an $839 billion defense spending bill that allocated $7.6 billion for 47 F-35 Joint Strike Fighters and $474 million in additional funding for the EA-37B Compass Call electronic warfare aircraft[2]. VisionWave Holdings (NASDAQ:VWAV), Kratos Defense & Security Solutions (NASDAQ:KTOS), ParaZero Technologies (NASDAQ:PRZO), Innoviz Technologies (NASDAQ:INVZ),

    2/17/26 10:25:03 AM ET
    $BBAI
    $INVZ
    $KTOS
    Computer Software: Prepackaged Software
    Technology
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    FTFT Announces Agreement with S1Quant to Explore the New Blue Ocean of Compliant Cryptocurrency Asset Management

    NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Future FinTech Group Inc. (NASDAQ:FTFT, ", Future FinTech", , ", FTFT", , or the ", Company", )), a comprehensive financial and digital technology service provider, today announced that on December 29, 2025, its wholly-owned subsidiary, FTFT International Securities and Futures Limited ("FTFT Securities"), signed a Letter of Intent for Strategic Cooperation agreement (the "Agreement") with S1Quant in the field of cryptocurrency asset management. The two parties have agreed to join hands to establish long-term, in-depth cooperation in the field of cryptocurrency asset management and jointly promote the development of a compliant and professional cryptocu

    1/5/26 8:30:00 AM ET
    $FTFT
    Real Estate

    $AUVI
    $BCEL
    $BRQS
    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ReTo Eco-Solutions Inc.

    SC 13G/A - ReTo Eco-Solutions, Inc. (0001687277) (Subject)

    12/3/24 8:32:02 AM ET
    $RETO
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by ReTo Eco-Solutions Inc.

    SC 13G/A - ReTo Eco-Solutions, Inc. (0001687277) (Subject)

    12/3/24 8:31:02 AM ET
    $RETO
    Industrial Machinery/Components
    Industrials